Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-REVERT
2023-507569-24-00Phase 2Completed
- Sponsor
- Cardior Pharmaceuticals
- Start
- Oct 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of CDR132L in myocardial infarction (MI) and Left Heart Failure (3 arms), sponsored by Cardior Pharmaceuticals. Primary endpoint: Percent change from baseline in LVESVI at Month 6. Started Oct 2024; status: completed.
02
Drugs
CDR132L
03
Conditions
myocardial infarction (MI)Left Heart Failure
Beyond the preview
Go deeper on 2023-507569-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507569-24-00.